KRRO
BEARISH
$12.68
Live
Korro Bio, Inc. · NASDAQ
Target $20.0
(+57.7%)
$5.2
52W Range
$55.89
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$182.88M
P/E
N/A
ROE
-110.7%
Profit margin
N/A
Debt/Equity
0.85
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.
Key Strengths
Strong short-term liquidity (Current Ratio: 6.90)
Recent trend of beating EPS estimates (2/4 last quarters)
Significant upside gap to analyst target price ($20.00)
Low Debt/Equity ratio (0.85) compared to sector average
Positive Q/Q EPS growth (+14.1%)
Key Risks
Extreme cash burn reflected in -1229.33% operating margin
Severe revenue contraction (-43.10% YoY)
Critical fundamental health (Piotroski F-Score: 1/9)
Extreme long-term price erosion (5Y Change: -97.3%)
Highly inflated Price/Sales ratio (28.61)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
30
10
20
0
AI Verdict
High-Risk Speculative
Key drivers: Catastrophic operating margins, Negative revenue growth, Poor Piotroski health score, Strong liquidity buffer
Confidence
90%
Value
15/100
Ref P/E N/A, P/S 28.61, Graham Number None
Positives
- P/B ratio is relatively moderate at 2.32
Watchpoints
- P/S ratio of 28.61 is excessively high for declining revenue
- No earnings to support a P/E valuation
Future
30/100
Ref Growth rates and Analyst Targets
Positives
- Analyst target price suggests potential recovery
Watchpoints
- Revenue growth is sharply negative (-43.10%)
- Forward P/E remains negative
Past
10/100
Ref Historical price performance
Positives
- Recent 1-month price bounce (+7.8%)
Watchpoints
- Devastating 5-year return (-97.3%)
- Severe 6-month decline (-70.5%)
Health
20/100
Ref Piotroski F-Score 1/9
Positives
- High Current Ratio (6.90) and Quick Ratio (6.38)
Watchpoints
- Piotroski F-Score of 1/9 indicates systemic weakness
- ROE of -110.70% shows massive capital erosion
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- Zero dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.68
Analyst Target
$20.0
Upside/Downside
+57.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KRRO and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KRRO
Korro Bio, Inc.
Primary
|
-97.3% | -46.2% | -2.2% | -70.5% | +7.8% | -9.4% |
|
KPTI
Karyopharm Therapeutics Inc.
Peer
|
-94.7% | -87.2% | +100.5% | +45.5% | -8.6% | +35.8% |
|
LFCR
Lifecore Biomedical, Inc.
Peer
|
-52.8% | +24.4% | -17.0% | -26.9% | -30.2% | +23.7% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
|
INGN
Inogen, Inc.
Peer
|
-88.6% | -52.4% | -10.6% | -22.4% | +1.6% | +1.9% |
KRR
Korro Bio, Inc.
Primary
5Y
-97.3%
3Y
-46.2%
1Y
-2.2%
6M
-70.5%
1M
+7.8%
1W
-9.4%
KPT
Karyopharm Therapeutics Inc.
Peer
5Y
-94.7%
3Y
-87.2%
1Y
+100.5%
6M
+45.5%
1M
-8.6%
1W
+35.8%
LFC
Lifecore Biomedical, Inc.
Peer
5Y
-52.8%
3Y
+24.4%
1Y
-17.0%
6M
-26.9%
1M
-30.2%
1W
+23.7%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
ING
Inogen, Inc.
Peer
5Y
-88.6%
3Y
-52.4%
1Y
-10.6%
6M
-22.4%
1M
+1.6%
1W
+1.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.67
PEG Ratio
N/A
P/B Ratio
2.32
P/S Ratio
28.61
EV/Revenue
23.66
EV/EBITDA
-1.82
Market Cap
$182.88M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1229.33%
Gross Margin
N/A
ROE
-110.7%
ROA
-32.14%
Growth
Revenue and earnings growth rates
Revenue Growth
-43.1%
Earnings Growth
N/A
Q/Q Revenue Growth
-43.11%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.85
Moderate
Current Ratio
6.9
Strong
Quick Ratio
6.38
Excellent
Cash/Share
$5.21
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-1229.3%
Net Margin
-3873.2%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
1.21x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-03-12
$-1.65
+22.9% surprise
2025-11-12
$-1.92
+28.3% surprise
2025-08-12
$-2.74
-5.6% surprise
Healthcare Sector Comparison
Comparing KRRO against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-110.7%
This Stock
vs
-49.88%
Sector Avg
+121.9%
(Excellent)
Debt to Equity
0.85
This Stock
vs
3.74
Sector Avg
-77.4%
(Less Debt)
Revenue Growth
-43.1%
This Stock
vs
80.78%
Sector Avg
-153.4%
(Slower)
Current Ratio
6.9
This Stock
vs
3.72
Sector Avg
+85.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KRRO
Korro Bio, Inc.
|
BEARISH | $182.88M | - | -110.7% | -% | $12.68 | |
|
KPTI
Karyopharm Therapeutics Inc.
|
BEARISH | $180.35M | - | -% | -134.2% | $8.0 | Compare |
|
LFCR
Lifecore Biomedical, Inc.
|
BEARISH | $178.02M | - | -% | -23.8% | $4.75 | Compare |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
|
INGN
Inogen, Inc.
|
BEARISH | $172.38M | - | -12.4% | -6.5% | $6.33 | Compare |
KRRO
Korro Bio, Inc.
BEARISH
Mkt Cap
$183M
P/E
-
ROE
-110.7%
Price
$12.68
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | Purchase | 520 | $5,512 |
| 2026-03-10 | BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | MATHERS EDWARD T. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | BEHBAHANI ALI | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 207,100 | $2,300,881 |
| 2026-03-10 | MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | SANDELL SCOTT D | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | WALKER PAUL EDWARD | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | YANG RICK | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-03-10 | NEW ENTERPRISE ASSOCIATES 17 L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 207,100 | $2,300,881 |
| 2026-02-02 | AIYAR RAM PH.D. | Chief Executive Officer | Stock Award | 40,000 | - |
| 2025-12-15 | CHAPPELL TODD | Chief Operating Officer | Stock Award | 20,132 | - |
| 2025-12-15 | CERIO JEFFREY | General Counsel | Stock Award | 41,902 | - |
| 2025-12-15 | DOLAN OLIVER | Officer | Stock Award | 21,482 | - |
LYNX1 CAPITAL MANAGEMENT LP
Beneficial Owner of more than 10% of a Class of Security
2026-03-31
520 shares
·
$5,512
BASKETT FOREST
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
MATHERS EDWARD T.
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
FLORENCE ANTHONY A JR
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
BEHBAHANI ALI
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
MAKHZOUMI MOHAMAD
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
CHANG CARMEN
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
SANDELL SCOTT D
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
WALKER PAUL EDWARD
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
YANG RICK
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
NEW ENTERPRISE ASSOCIATES 17 L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-03-10
207,100 shares
·
$2,300,881
AIYAR RAM PH.D.
Chief Executive Officer
2026-02-02
40,000 shares
CHAPPELL TODD
Chief Operating Officer
2025-12-15
20,132 shares
CERIO JEFFREY
General Counsel
2025-12-15
41,902 shares
DOLAN OLIVER
Officer
2025-12-15
21,482 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
Cantor Fitzgerald
2026-03-13
Overweight
Overweight
Raymond James
2026-03-13
Market Perform
Outperform
Clear Street
2026-02-19
Hold
Buy
William Blair
2026-02-17
Market Perform
Outperform
Chardan Capital
2026-01-29
Neutral
Buy
HC Wainwright & Co.
2026-01-29
Neutral
Buy
Piper Sandler
2026-01-29
Neutral
Overweight
Oppenheimer
2026-01-28
Perform
Outperform
Cantor Fitzgerald
2026-01-28
Neutral
Overweight
Jones Trading
2025-11-14
Buy
Hold
Past News Coverage
Recent headlines mentioning KRRO from our newsroom.
Newest → oldest
No matching news yet.